Drug reference

umbralisib

PI3Kδ inhibitor · Antineoplastic agent

PI3Kδ inhibitorAntineoplastic agent

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

FDA category + note

Mechanism

Umbralisib is an orally bioavailable inhibitor of PI3Kδ with a greater than 100-fold selectivity versus PI3Kα, β, or γ. It also inhibits casein kinase ε.

Indications

marginal zone lymphoma after at least one prior therapyrelapsed or refractory FL after three prior therapies

Pharmacokinetics

Half-life

91 h (elimination)

Metabolism

CYP2C9, CYP3A4, and CYP1A2

Side effects

Serious

neutropenia
increased risk of infections
diarrhea
noninfectious colitis
hepatotoxicity

Pregnancy & lactation

Pregnancy

Related guidelines

Heart failure in diabetes

RSSDI · Cardiology · 2023

Hypertension in adults

ICMR · Cardiology · 2019

Generalised anxiety disorder and panic disorder

NICE · Psychiatry · 2020

Hypertrophic cardiomyopathy

ESC · Cardiology · 2026

Diabetes management in chronic kidney disease

KDIGO · Nephrology · 2022

Ask House about umbralisib

Continue into a citation-backed clinical answer with the drug context already attached.

Open in workspace Ask House about this drug

Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team